PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportstransitional cell carcinoma
MeSH D002295 - transitional cell carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D002277:Carcinoma
18 Companies
3 Drugs
$
Success rate
D002295: 
Transitional cell carcinoma
8 Companies
8 Drugs
$
Success rate
Events Timeline
Loading
Commercial
No Data
Clinical Trials
Historical Success Rate
Phase 1
65%
15/23
Phase 2
29%
15/52
Phase 3
35%
11/31
Approved: 9Overall Success rate: 7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Astellas Pharma
Enfortumab vedotin,
Gilvetmab,
Globulin, immune,
Mk3475
AstraZeneca
Durvalumab,
Gilvetmab,
Cediranib,
Bevifimod,
Nepidermin,
Polyglycolic acid,
VACTOSERTIB,
Globulin, immune,
AZD-4877,
Doxorubin,
Hydroxydaunomycin,
Docetaxol,
Isoxaflutole
Bristol Myers Squibb
Nivolumab,
Sacituzumab,
Bempegaldesleukin,
Gilvetmab,
Brivanib alaninate,
Bevifimod,
EGANELISIB,
Nepidermin,
Polyglycolic acid,
URELUMAB,
Globulin, immune,
Hiltonol,
Gemcis,
Docetaxol
EMD Serono
Avelumab,
Mk3475
Johnson & Johnson
Erdafitinib,
Cetrelimab
Laboratoires Pierre Fabre
Vinflunine,
Nepidermin
Merck & Co
Pembrolizumab,
Avelumab,
Sacituzumab,
Gilvetmab,
Epacadostat,
Aglatimagene besadenovec,
Zilovertamab,
Bevifimod,
Favezelimab,
Nepidermin,
Telbermin,
Vibostolimab,
VOFATAMAB,
Microcrystalline cellulose,
Globulin, immune,
Potassium magnesium citrate (4:1:2),
Mk3475,
Potassium nitrate,
Histone-arginine methyltransferase carm1,
Gemcis,
Surlorian,
Docetaxol,
Sacituzumab tirumotecan
Roche
Atezolizumab,
Sacituzumab,
Magrolimab,
Tiragolumab,
Epacadostat,
AUTOGENE CEVUMERAN,
Nepidermin,
Globulin, immune,
RO7122290,
Histone-arginine methyltransferase carm1,
Surlorian
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use